Vitality Watch

Dossier pubmed review 10-aug-2026
Narrative review or expert overview without new data

Chronic subdural hematoma through the hallmarks of aging: a geroscience framework for the commonest neurosurgical condition of older adults.

Key claim: Chronic subdural hematoma can be reframed as a geroscience disease whose pathogenesis maps onto the hallmarks of aging—with strongest support for chronic inflammation and altered intercellular communication—and may be a tractable target for mechanism-directed gerotherapeutics such as senolytics.

Abstract

Chronic subdural hematoma (CSDH) is among the commonest cranial neurosurgical conditions of older adults and is projected, on the basis of incidence modeling, to become the most common cranial neurosurgical condition in adults by 2030. Despite this clinical centrality, CSDH has not been formally examined through the conceptual lens of geroscience. This minireview reframes CSDH as a geroscience disease by mapping its pathogenesis onto the twelve hallmarks of aging articulated by López-Otín and colleagues. Two hallmarks have strong direct support in the existing CSDH literature. Chronic inflammation and altered intercellular communication both manifest in the inflammaging fingerprint of hematoma fluid and in the dysregulated paracrine signaling of the outer neomembrane. Cellular senescence is the most fertile moderate-evidence hallmark. The molecular signature of the senescence-associated secretory phenotype overlaps closely with the cytokine, chemokine, and matrix remodeling milieu of the CSDH cavity, but no study has yet demonstrated senescent cells in resected neomembrane tissue. Mitochondrial dysfunction, deregulated nutrient sensing, and loss of proteostasis have weak inferential support. Four hallmarks, namely, genomic instability, telomere attrition, epigenetic alterations, and stem cell exhaustion, are essentially unstudied in CSDH and are framed as research priorities. Disabled macroautophagy and dysbiosis have recently received initial direct measurements but remain only partially addressed. The 2024 randomized trials of middle meningeal artery embolization, the success of atorvastatin in the ATOCH trial, and emerging senolytic clinical translation collectively suggest that CSDH may be a tractable target for future mechanism-directed gerotherapeutic interventions. The most actionable contribution of this framework is to specify which experiments would convert CSDH from a surgical emergency of older adults into an exemplar of clinical geroscience.

Why this matters

Chronic subdural hematoma is the most common neurosurgical condition in older adults and is currently treated with drainage, not biology — this review is the first formal attempt to pull it into the geroscience frame by mapping its dural neomembrane pathology onto the twelve hallmarks of aging. It nominates chronic inflammation and altered intercellular communication as the strongest mechanistic contributors and senolytics as candidate mechanism-directed gerotherapeutics, but no gerotherapeutic has been tested against CSDH endpoints and the proposal is a research agenda rather than a treatment paradigm.

Source

Link

Briefing card

Chronic subdural hematoma through the hallmarks of aging: a geroscience framework for the commonest neurosurgical condition of older adults.
Stage: review · pubmed · 10-aug-2026

If you or an older relative are facing chronic subdural hematoma, this review argues the condition shares biology with aging itself but does not change current treatment — it only sets a research agenda for drugs like atorvastatin and senolytics.

Chronic subdural hematoma can be reframed as a geroscience disease whose pathogenesis maps onto the hallmarks of aging—with strongest support for chronic inflammation and altered intercellular communication—and may be a tractable target for mechanism-directed gerotherapeutics such as senolytics.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1007/s11357-026-02470-x

build build 880 · 2bcef25 · 2026-11-18